← Dashboard
Stock
ALNY
ALNYLAM PHARMACEUTICALS, INC.Latest close $2864 of 27 marquee funds currently hold2 CUSIPs mapped
Current holders
4
27 funds tracked
Ever held
10
Current + past
New this quarter
1
Exited this quarter
0
Marquee-fund ownership over time
Aug 14, 2018Nov 14, 2022Feb 14, 2025May 15, 2026
Now
7
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q3 2021 | 20Q | $197 | $286 | +46% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $263 | $286 | +9% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $286 | — |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $263 | $286 | +9% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 2× in & out | Q2 2025 | Q1 2026 | → $333 | +17% |
| Soros Fund Management 2× in & out | Q4 2025 | Q1 2026 | → $314 | -30% |
| Citadel Advisors 3× in & out | Q2 2025 | Q4 2025 | — | +0% |
| Millennium Management 3× in & out | Q3 2025 | Q4 2025 | — | +0% |
| Duquesne Family Office 3× in & out | Q4 2022 | Q2 2023 | → $206 | -3% |
| Maverick Capital | Q3 2018 | Q1 2022 | → $149 | +60% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at ALNYLAM PHARMACEUTICALS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
12
Filings · last 90d
18
Total on file
566
Recent SEC buffer
Most recent
Jun 3, 2026
30d / 90d windows measured from Jun 3, 2026 — the most recent Form 4 on file — not from today.
- Form 40001178670-26-000048Jun 3, 2026
- Form 40001178670-26-000047Jun 3, 2026
- Form 40001178670-26-000042May 22, 2026
- Form 40001178670-26-000041May 22, 2026
- Form 40001178670-26-000040May 22, 2026
- Form 40001178670-26-000039May 22, 2026
- Form 40001178670-26-000038May 22, 2026
- Form 40001178670-26-000037May 22, 2026
- Form 40001178670-26-000036May 22, 2026
- Form 40001178670-26-000035May 22, 2026
- Form 40001178670-26-000034May 22, 2026
- Form 40001178670-26-000017May 14, 2026
- Form 40001178670-26-000014Apr 7, 2026
- Form 40001735276-26-000063Mar 6, 2026
- Form 40001735276-26-000062Mar 6, 2026
Showing 15 of 566 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · ALNYLAM PHARMACEUTICALS, INC.Annual figures sourced directly from ALNYLAM PHARMACEUTICALS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$3.71B
FY2025+65% YoY
Net income
$313.75M
FY2025+55% YoY
EPS (diluted)
$2.33
FY2025+54% YoY
Free cash flow(?)
$465.38M
FY2025+500%+ YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for ALNYLAM PHARMACEUTICALS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 27, 2026
- 10-QQuarterly reportApr 30, 2026
- 8-KMaterial eventApr 30, 2026
- DEF 14AProxy statementApr 6, 2026
- 8-KMaterial eventMar 4, 2026
- 10-KAnnual reportFeb 12, 2026
- 8-KMaterial eventFeb 12, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventDec 11, 2025
- 8-KMaterial eventDec 3, 2025
- 10-QQuarterly reportOct 30, 2025
- 8-KMaterial eventOct 30, 2025
- 8-KMaterial eventOct 3, 2025
- 8-KMaterial eventSep 12, 2025
- 8-KMaterial eventSep 10, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q2 2026 | open | $0.00 | — | +0% |
| Soros Fund Management | Q4 2025 | Q1 2026 | $449 | $314 | -30% |
| Bridgewater Associates | Q4 2025 | open | $454 | $286 | -37% |
| Millennium Management | Q3 2025 | Q4 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q2 2025 | Q4 2025 | $0.00 | — | +0% |
| Soros Fund Management | Q2 2025 | Q3 2025 | $283 | $443 | +56% |
| Point72 Asset Management | Q2 2025 | Q3 2025 | $0.00 | — | +0% |
| Point72 Asset Management | Q2 2025 | Q1 2026 | $283 | $333 | +17% |
| Millennium Management | Q4 2024 | Q1 2025 | $0.00 | — | +0% |
| Bridgewater Associates | Q4 2024 | Q2 2025 | $265 | $268 | +1% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | open | $263 | $286 | +9% |
| Two Sigma Investments | Q3 2024 | open | $263 | $286 | +9% |
| D.E. Shaw | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | open | $263 | $286 | +9% |
| AQR Capital Management | Q3 2024 | open | $263 | $286 | +9% |
| Millennium Management | Q3 2024 | open | $263 | $286 | +9% |
| Bridgewater Associates | Q2 2023 | Q2 2024 | $205 | $148 | -28% |
| Duquesne Family Office | Q4 2022 | Q2 2023 | $213 | $206 | -3% |
| Bridgewater Associates | Q3 2022 | Q1 2023 | $229 | $222 | -3% |
| Duquesne Family Office | Q2 2022 | Q3 2022 | $125 | $231 | +85% |
| Bridgewater Associates | Q3 2021 | Q1 2022 | $197 | $149 | -24% |
| Duquesne Family Office | Q1 2020 | Q1 2021 | $129 | $154 | +20% |
| Maverick Capital | Q3 2018 | Q1 2022 | $93 | $149 | +60% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.